NO792398L - Anvendelse av sarkosin og sarkosinderivater som tumorhemmende bestanddeler, og fremgangsmaate ved fremstillinhg av disse - Google Patents
Anvendelse av sarkosin og sarkosinderivater som tumorhemmende bestanddeler, og fremgangsmaate ved fremstillinhg av disseInfo
- Publication number
- NO792398L NO792398L NO792398A NO792398A NO792398L NO 792398 L NO792398 L NO 792398L NO 792398 A NO792398 A NO 792398A NO 792398 A NO792398 A NO 792398A NO 792398 L NO792398 L NO 792398L
- Authority
- NO
- Norway
- Prior art keywords
- sarcosine
- tumor
- combination
- anhydride
- series
- Prior art date
Links
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 title claims abstract description 166
- 238000002360 preparation method Methods 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 12
- 102100037644 Kelch-like protein 41 Human genes 0.000 title description 4
- 108050003242 Kelch-like protein 41 Proteins 0.000 title description 4
- NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 title description 4
- 239000004615 ingredient Substances 0.000 title 1
- 229940043230 sarcosine Drugs 0.000 claims abstract description 81
- 108010077895 Sarcosine Proteins 0.000 claims abstract description 74
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- GPAYXCOQADGNAZ-UHFFFAOYSA-N [2-(methylamino)acetyl] 2-(methylamino)acetate Chemical compound CNCC(=O)OC(=O)CNC GPAYXCOQADGNAZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 150000001408 amides Chemical class 0.000 claims abstract description 8
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 8
- 238000009830 intercalation Methods 0.000 claims abstract description 8
- -1 alkyl glycines Chemical class 0.000 claims abstract description 5
- 230000000340 anti-metabolite Effects 0.000 claims abstract description 4
- 229940100197 antimetabolite Drugs 0.000 claims abstract description 4
- 239000002256 antimetabolite Substances 0.000 claims abstract description 4
- 230000002195 synergetic effect Effects 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 31
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 20
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 13
- 150000008064 anhydrides Chemical class 0.000 claims description 11
- 229940109239 creatinine Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000005907 alkyl ester group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- BHUGZIJOVAVBOQ-UHFFFAOYSA-N 2-(propylazaniumyl)acetate Chemical compound CCCNCC(O)=O BHUGZIJOVAVBOQ-UHFFFAOYSA-N 0.000 claims description 2
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 claims description 2
- 108010065338 N-ethylglycine Proteins 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 54
- 241001465754 Metazoa Species 0.000 description 23
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 18
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 17
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 13
- 229960004316 cisplatin Drugs 0.000 description 13
- 229940009456 adriamycin Drugs 0.000 description 11
- 230000000973 chemotherapeutic effect Effects 0.000 description 10
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 201000000274 Carcinosarcoma Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UUYDPHCMCYSNAY-UHFFFAOYSA-N 2-amino-n-methylacetamide Chemical compound CNC(=O)CN UUYDPHCMCYSNAY-UHFFFAOYSA-N 0.000 description 3
- FDYLEQIJNGFKPH-UHFFFAOYSA-N 2-amino-n-propylacetamide Chemical compound CCCNC(=O)CN FDYLEQIJNGFKPH-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 3
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108700003203 N-methylglycinamide Proteins 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 208000008342 Leukemia P388 Diseases 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- IEPCYJLTAGEWNI-CULQTAMWSA-N (5s,5ar)-5-[[(2r)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3[C@@H](OC3C(C(O)C4O[C@H](C)OCC4O3)O)[C@@H]3C2C(OC3)=O)=C1 IEPCYJLTAGEWNI-CULQTAMWSA-N 0.000 description 1
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical class NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 1
- NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 description 1
- FRYOUKNFWFXASU-UHFFFAOYSA-N 2-(methylamino)acetic acid Chemical compound CNCC(O)=O.CNCC(O)=O FRYOUKNFWFXASU-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002786 epipodophyllotoxin derivative Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 150000002542 isoureas Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
- Toys (AREA)
- Window Of Vehicle (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19782832009 DE2832009A1 (de) | 1978-07-20 | 1978-07-20 | Verwendung von sarkosin und sarkosinderivaten ls tumorhemmende wirksubstanzen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO792398L true NO792398L (no) | 1980-01-22 |
Family
ID=6044955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO792398A NO792398L (no) | 1978-07-20 | 1979-07-19 | Anvendelse av sarkosin og sarkosinderivater som tumorhemmende bestanddeler, og fremgangsmaate ved fremstillinhg av disse |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4766149A (fr) |
| EP (1) | EP0007597B1 (fr) |
| JP (1) | JPS5519270A (fr) |
| AT (1) | ATE11220T1 (fr) |
| AU (1) | AU529657B2 (fr) |
| CA (1) | CA1151065A (fr) |
| DD (1) | DD144864A5 (fr) |
| DE (1) | DE2832009A1 (fr) |
| DK (1) | DK305479A (fr) |
| FI (1) | FI792218A (fr) |
| MC (1) | MC1271A1 (fr) |
| NO (1) | NO792398L (fr) |
| ZA (1) | ZA793603B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3050800C2 (fr) * | 1979-03-22 | 1989-06-22 | Continental Pharma Inc., Bruessel/Bruxelles, Be | |
| DE3440090A1 (de) * | 1984-11-02 | 1986-05-07 | Novo-Med AG, Appenzell | Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung |
| US4916217A (en) * | 1987-01-08 | 1990-04-10 | Bristol-Myers Company | Phosphorus containing derivatives of epipodophyllotoxin |
| US4994492A (en) * | 1989-01-09 | 1991-02-19 | Foodscience Corporation | Treatment of melanoma using N,N-dimethylglycine |
| US5676978A (en) * | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| DE4026184A1 (de) * | 1990-08-18 | 1992-02-20 | Henkel Kgaa | Verfahren zur verminderung des restgehaltes an freiem alkylierungsmittel in waessrigen loesungen kationischer tenside |
| JP2005529980A (ja) * | 2002-06-19 | 2005-10-06 | ネムローゼ・フェンノートシャップ・ニュートリシア | 代謝ストレスを受けている哺乳動物における異化を治療または予防し、同化を促進する方法及び組成物 |
| US8697679B2 (en) * | 2003-03-07 | 2014-04-15 | N.V. Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| EP1847274A1 (fr) * | 2006-04-21 | 2007-10-24 | CIPROSA LLC - Corporate Creations Network, Inc. | Association de phényl butyrate, ATRA et cytidine et son utilisation dans la thérapie antitumorale |
| EP3415910A1 (fr) | 2017-06-16 | 2018-12-19 | Prevention Medicals s.r.o. | Procédé de détermination quantitative de sarcosine dans un échantillon biologique au moyen d'anticorps anti-sarcosine et de nanoparticules d'or à peroxidase-active ou de points quantiques |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE553424C (de) * | 1928-04-18 | 1932-06-27 | Karl Luedecke Dr | Verfahren zur Herstellung von Praeparaten, die das Wachstum von Geweben durch Verminderung der Teilungsfaehigkeit oder Aufloesung der wuchernden Zellen einschraenken |
| BE647556A (fr) * | 1964-05-06 | 1964-08-31 | ||
| FR2085637A1 (fr) * | 1970-04-15 | 1971-12-31 | Etude Des Catalyseurs Soc D | Composition pharmaceutique utilisable notamment contre l'asthenie |
| DE2211019C3 (de) * | 1972-03-08 | 1980-08-28 | Bayer Ag, 5090 Leverkusen | Geschmacksverbessernde Formulierungen oraler Penicilline |
-
1978
- 1978-07-20 DE DE19782832009 patent/DE2832009A1/de active Granted
-
1979
- 1979-07-16 FI FI792218A patent/FI792218A/fi not_active Application Discontinuation
- 1979-07-17 ZA ZA00793603A patent/ZA793603B/xx unknown
- 1979-07-18 CA CA000332027A patent/CA1151065A/fr not_active Expired
- 1979-07-19 MC MC791396A patent/MC1271A1/fr unknown
- 1979-07-19 JP JP9209779A patent/JPS5519270A/ja active Pending
- 1979-07-19 NO NO792398A patent/NO792398L/no unknown
- 1979-07-19 AU AU49076/79A patent/AU529657B2/en not_active Ceased
- 1979-07-19 DD DD79214469A patent/DD144864A5/de unknown
- 1979-07-19 DK DK305479A patent/DK305479A/da not_active Application Discontinuation
- 1979-07-20 AT AT79102577T patent/ATE11220T1/de not_active IP Right Cessation
- 1979-07-20 EP EP79102577A patent/EP0007597B1/fr not_active Expired
-
1986
- 1986-05-08 US US06/861,753 patent/US4766149A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4766149A (en) | 1988-08-23 |
| AU529657B2 (en) | 1983-06-16 |
| ZA793603B (en) | 1980-07-30 |
| DD144864A5 (de) | 1980-11-12 |
| FI792218A (fi) | 1980-01-21 |
| AU4907679A (en) | 1980-01-24 |
| DE2832009A1 (de) | 1980-01-31 |
| MC1271A1 (fr) | 1980-05-23 |
| ATE11220T1 (de) | 1985-02-15 |
| EP0007597A1 (fr) | 1980-02-06 |
| JPS5519270A (en) | 1980-02-09 |
| EP0007597B1 (fr) | 1985-01-16 |
| DK305479A (da) | 1980-01-21 |
| DE2832009C2 (fr) | 1988-07-28 |
| CA1151065A (fr) | 1983-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Creighton et al. | Antitumour activity in a series of bis diketopiperazines | |
| DE2556100C2 (fr) | ||
| AU2009210356B2 (en) | Formulations and methods of administration of cephalotaxines, including homoharringtonine | |
| JPH05503914A (ja) | 細胞増殖の抑制及びｎｋ細胞活性の増強 | |
| NO792398L (no) | Anvendelse av sarkosin og sarkosinderivater som tumorhemmende bestanddeler, og fremgangsmaate ved fremstillinhg av disse | |
| AT395111B (de) | Verfahren zur herstellung von infusionsloesungen zur pareuteralen ernaehrung | |
| US4160826A (en) | Inhibitor preparation for the absorption of lipids, based on diethylaminoethyldextran | |
| NO324974B1 (no) | Anvendelse av 3-amino-1,2,4-benzotriazin-1,4-dioksyd/paclitaxel/platina for fremstilling av et preparat for behandling av et pattedyr som har en fast tumor samt kit inneholdende nevnte preparat. | |
| WO1991002529A2 (fr) | Produit et methode pour tuer les cellules anormales chez les vertebres | |
| CN110664807B (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
| FI78069C (fi) | Foerfarande foer framstaellning av saosom laekemedel anvaendbara acylerade enamidfoereningar. | |
| US3179562A (en) | Treatment of diabetes with alpha, alpha substituted acetic acid derivatives | |
| US5710179A (en) | Antitumor agent | |
| FR2609893A1 (fr) | Composition a base d'acides amines et de vitamines utilisable en therapeutique cancerologique | |
| RU2174833C1 (ru) | Препарат для профилактики и лечения кокцидиоза птиц | |
| DE2748015A1 (de) | Arzneimittel zur heilung von boesartigen neubildungen | |
| US7863337B2 (en) | Use of triacontanol in preparation of medicaments for treatment of cancers | |
| IE49181B1 (en) | Treatment of malignancies by administering sarcosine,its derivatives and mixtures | |
| KR102028383B1 (ko) | 난청의 예방 또는 치료용 조성물 | |
| US3646213A (en) | Compositions and methods for treating depression with combinations of l-3 4-dihydroxyphenylalanine and a hydrazine | |
| GB2081089A (en) | Method of preparing a ginseng injection | |
| US3317391A (en) | Composition for treatment of angina pectoris and process for preparing same | |
| CN116407547A (zh) | 一种玫瑰红景天中活性成分Rosavins、包含Rosavins的制剂及其应用 | |
| RU2550916C1 (ru) | Фармацевтическая композиция для лечения заболеваний опорно-двигательного аппарата | |
| US3755567A (en) | Method for treating alcoholism |